Progen. Co., Ltd.

This study tests whether people with type 2 diabetes can switch from a weekly injection of dulaglutide to a once-monthly shot called PG-102. The trial involves 60 adults whose blood sugar is well-controlled on dulaglutide. Researchers will compare blood sugar levels and safety ov…

This Phase 2 study tests an experimental drug called PG-102, given as a weekly injection, in 80 adults with type 2 diabetes. Participants will receive either PG-102, a placebo, or the approved drug semaglutide for 24 weeks. The main goal is to see how well PG-102 lowers blood sug…